Diarrhea Drug Abuse Shouldn't End OTC Sales, FDA Hears

Law360, New York (September 11, 2017, 3:20 PM EDT) -- Over-the-counter sales of Johnson & Johnson’s diarrhea drug Imodium A-D shouldn't be halted despite an uptick in fatal overdoses, a top trade group told the U.S. Food and Drug Administration in a letter released Monday.

In a letter to the FDA, the Consumer Healthcare Products Association opposed a pending citizen petition that calls for Imodium and other loperamide drugs to lose their OTC status. The petition, submitted in December by a U.S. Department of Veterans Affairs physician, followed an FDA safety alert about abuse of loperamide...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.